Johnson & Johnson
J&J withdraws controversial vaginal mesh from Australian market
January 23, 2018Manufacturing and Production, Sales and Marketing J&J, JJ, Johnson & Johnson, lawsuit, pharma, vaginal mesh
Johnson & Johnson has withdrawn its controversial vaginal mesh product from the Australian market after missing a deadline requiring all …
Top Ten most popular articles on Pharmafile.com this week
January 12, 2018Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Bayer, HIV, J&J, JJ, Johnson & Johnson, Pfizer, Shire, Teva, Xarelto, patient reported outcomes
The Xmas break is now a distant memory as we move further into January, and with another Friday comes another …
Bayer and J&J successfully reverse $28 million Xarelto court payout
January 10, 2018Research and Development, Sales and Marketing Bayer, J&J, JJ, Johnson & Johnson, Xarelto, pharma
Bayer and Johnson & Johnson have managed to avert a payout of $27.8 million after a Pennsylvania state court judge …
J&J’s predicted blockbuster depression posts P2 data
January 3, 2018Research and Development Johnson & Johnson, biotech, depression, drugs, pharma, pharmaceutical
Johnson & Johnson has revealed Phase 2 data for its treatment for depression, esketamine, and the results are positive. The …
Pharmafile.com’s top ten stories of 2017
December 22, 2017Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Abbott, Actelion, Amgen, AstraZeneca, Cyber attack, EMA, European Commission, Humira, J&J, JJ, Johnson & Johnson, MSD, Sanofi, Shire, Teva, biosimilar, brexit
After a packed year that has flown by, we’ve reached the final top ten of 2017. Below you can find …
J&J struck by €25m fine over fentanyl pain patch
December 20, 2017Research and Development, Sales and Marketing Johnson & Johnson, biotech, drugs, fentanyl, pharma, pharmaceutical
Johnson & Johnson has been fined by France’s competition authority, Autorité de la Concurrence, after it alleges the company had …
What will Pfizer do with its second Remicade biosimilar?
December 14, 2017Sales and Marketing Ixifi, Johnson & Johnson, Pfizer, Remicade, biosimilars, biotech, drugs, inflectra, pharma, pharmaceutical
Pfizer is now in the unusual position of owning two biosimilars to Johnson & Johnson’s Remicade, though one of these …
J&J’s Darzalex cuts risk of disease progression and death by 50%, new study shows
December 13, 2017Research and Development Genmab, J&J, JJ, Janssen, Johnson & Johnson, darzalex, multiple myeloma, pharma
Johnson and Johnson has revealed data which demonstrates that Darzalex (daratumumab), when combined with a regimen of bortezomib, melphalan and …
J&J opts in on Idorsia’s candidate for $230m
December 4, 2017Sales and Marketing Idorsia, Johnson & Johnson, biotech, drugs, pharma, pharmaceutical
As part of Johnson & Johnson’s acquisition of Actelion, it was able to secure a number of ties with the …
$417 million case against J&J thrown out
October 23, 2017Sales and Marketing Johnson & Johnson, biotech, drugs, pharma, pharmaceutical, talc
A judge in California has thrown out the lawsuit made by a woman who had alleged that Johnson & Johnson’s …
J&J’s third quarter: The good and the bad
October 18, 2017Medical Communications, Research and Development, Sales and Marketing J&J, JJ, Janssen, Johnson & Johnson, biotech, drugs, pharma, pharmaceutical
It was a mixed bag for Johnson & Johnson on its announcement of third quarter results. It could largely be …
J&J exits insulin pump business, rival looks to scoop patients
October 10, 2017Manufacturing and Production Johnson & Johnson, biotech, diabetes, drugs, pharma, pharmaceutical
Johnson & Johnson’s Animas Corporation will cease business and close operations after the pharma giant could not find a buyer …
FDA rejects J&J’s treatment for rheumatoid arthritis
September 25, 2017Sales and Marketing Johnson & Johnson, biotech, drugs, pharma, pharmaceutical, sirukumab
Perhaps unsurprisingly, after the FDA’s advisory committee had voted 12-1 against approval of Johnson & Johnson’s drug, the FDA returned …
J&J backs out of $1.1 billion hep C deal, wiping 22.2% from Achillion’s stock
September 12, 2017Manufacturing and Production, Sales and Marketing J&J, JJ, Johnson & Johnson, achillion, hepatitis C, pharma
Johnson & Johnson has announced that it is to back out of a $1.1 billion deal with Achillion Pharmaceuticals to …
J&J offers $134,000 grant to find the best start-up in South Korea
August 31, 2017Research and Development J&J. pharma, Johnson & Johnson, drugs, life sciences, medicine, pharmaceutical, south korea
Johnson & Johnson is doubling down its efforts to grow its business in East Asia by identifying and recruiting promising …
Latest content
Five Facts about cardiovascular disease
